Stenoses, Aortic Valve Clinical Trial
Official title:
REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China
| Verified date | November 2023 |
| Source | Boston Scientific Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To evaluate the safety and effectiveness of the Lotus Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic Chinese patients with calcific, severe native aortic stenosis who are considered at high risk for surgical valve replacement.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | November 30, 2020 |
| Est. primary completion date | November 30, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 70 Years and older |
| Eligibility | Inclusion Criteria: - Age = 70 years. - Subject has documented calcific, severe native aortic stenosis with an initial AVA of <1.0 cm2 (or AVA index of <0.6 cm2/m2), and a mean pressure gradient =40 mm Hg or jet velocity =4.0 m/s or doppler velocity index =0.25, as measured by echocardiography and/or invasive hemodynamics. - Subject has a documented aortic annulus size of =20 mm and =27 mm based on the center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case Review Committee [CRC]). - Subject has symptomatic aortic valve stenosis with NYHA Functional Class = II. - There is agreement by the heart team (which must include a site investigator interventionalist and a site investigator cardiac surgeon) that subject is at high operative risk for surgical valve replacement (see note below for definition of high risk, the required level of surgical assessment, and CRC confirmation) and that TAVR is appropriate. Additionally, subject has at least one of the following. - Society of Thoracic Surgeons (STS) score = 8% -OR- - If STS < 8%, subject has at least one of the following conditions: - Hostile chest - Porcelain aorta - Severe pulmonary hypertension (> 60 mmHg) - Prior chest radiation therapy - Coronary artery bypass graft(s) at risk with re-operation - Severe lung disease (need for supplemental oxygen, FEV1 < 50% of predicted, DLCO < 60%, or other evidence of severe pulmonary dysfunction) - Neuromuscular disease that creates risk for mechanical ventilation or rehabilitation after surgical aortic valve replacement - Orthopedic disease that creates risk for rehabilitation after surgical aortic valve replacement - Childs Class A or B liver disease (subjects with Childs Class C disease are not eligible for inclusion in this trial) - Frailty as indicated by at least one of the following: 5-meter walk > 6 seconds, Katz ADL score of 3/6 or less, body mass index < 21, wheelchair bound, unable to live independently - Age = 90 years - Other evidence that subject is at high risk for surgical valve replacement (CRC must confirm agreement with site heart team that subject meets high risk definition) - Heart team (which must include a cardiac interventionalist and an experienced cardiac surgeon) assessment that the subject is likely to benefit from valve replacement. - Subject (or legal representative) understands the study requirements and the treatment procedures, and provides written informed consent - Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all required scheduled follow up visits. Exclusion Criteria: - Subject has a congenital unicuspid aortic valve or Sievers Type 2 bicuspid aortic valve. - Subject has had an acute myocardial infarction within 30 days prior to the index procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation = twice normal in the presence of CK-MB elevation and/or troponin elevation). - Subject has had a cerebrovascular accident or transient ischemic attack within the past 6 months prior to study enrollment. - Subject has end-stage renal disease or has serum creatinine > 3mg/dl or has creatinine clearance rate <45ml/min. - Subject has a pre-existing prosthetic aortic or mitral valve. - Subject has severe (4+) aortic, tricuspid, or mitral regurgitation. - Subject has a need for emergency surgery for any reason. - Subject has a history of endocarditis within 6 months of index procedure or evidence of an active systemic infection or sepsis. - Subject has echocardiographic evidence of new intra-cardiac vegetation or intraventricular or paravalvular thrombus requiring intervention. - Subject has platelet count < 50,000 cells/mm3 (50×109/L) or > 700,000 cells/mm3 (700×109/L), or white blood cell count < 1,000 cells/mm3 (1×109/L). - Subject requires chronic anticoagulation therapy after the implant procedure and cannot be treated with warfarin (other anticoagulants are not permitted in the first month) for at least 1 month concomitant with either aspirin or clopidogrel. - Subject has had a gastrointestinal bleed requiring hospitalization or transfusion within the past 3 months, or has other clinically significant bleeding diathesis or coagulopathy that would preclude treatment with required antiplatelet regimen, or will refuse transfusions - Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated, or has known hypersensitivity to aspirin, all P2Y12 inhibitors, heparin, nickel, tantalum, titanium, or polyurethanes - Subject has a life expectancy of less than 12 months due to non-cardiac, comorbid conditions based on the assessment of the investigator at the time of enrollment - Subject has hypertrophic obstructive cardiomyopathy - Subject has any therapeutic invasive cardiac or vascular procedure within 30 days prior to the index procedure (except for balloon aortic valvuloplasty or pacemaker implantation, which is allowed) - Subject has untreated coronary artery disease, which in the opinion of the treating physician is clinically significant and requires revascularization - Subject has severe left ventricular dysfunction with ejection fraction < 20% - Subject is in cardiogenic shock or has hemodynamic instability requiring inotropic support or mechanical support devices - Subject has severe vascular disease that would preclude safe access (e.g., aneurysm with thrombus that cannot be crossed safely, marked tortuosity, significant narrowing of the abdominal aorta, severe unfolding of the thoracic aorta, or symptomatic carotid or vertebral disease) - Subject has thick (> 5 mm) protruding or ulcerated atheroma in the aortic arch - Subject has an enlarged ascending aorta with the diameter > 50mm - Subject has arterial access that is not acceptable for the study device delivery system as defined in the device Instructions For Use - Subject has current problems with substance abuse (e.g., alcohol, etc.) - Subject is participating in another investigational drug or device study that has not reached its primary endpoint - Subject has untreated conduction system disorder (e.g., Type II second degree atrioventricular block) that in the opinion of the treating physician is clinically significant and requires a pacemaker implantation. Enrollment is permissible after permanent pacemaker implantation - Subject has severe incapacitating dementia |
| Country | Name | City | State |
|---|---|---|---|
| China | Cardiovascular Institute and Fu Wai Hospital | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Boston Scientific Corporation | Quintiles, Inc. |
China,
American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Bonow RO, Carabello BA, Kanu — View Citation
Barreto-Filho JA, Wang Y, Dodson JA, Desai MM, Sugeng L, Geirsson A, Krumholz HM. Trends in aortic valve replacement for elderly patients in the United States, 1999-2011. JAMA. 2013 Nov 20;310(19):2078-85. doi: 10.1001/jama.2013.282437. — View Citation
Ben-Dor I, Pichard AD, Gonzalez MA, Weissman G, Li Y, Goldstein SA, Okubagzi P, Syed AI, Maluenda G, Collins SD, Delhaye C, Wakabayashi K, Gaglia MA Jr, Torguson R, Xue Z, Satler LF, Suddath WO, Kent KM, Lindsay J, Waksman R. Correlates and causes of death in patients with severe symptomatic aortic stenosis who are not eligible to participate in a clinical trial of transcatheter aortic valve implantation. Circulation. 2010 Sep 14;122(11 Suppl):S37-42. doi: 10.1161/CIRCULATIONAHA.109.926873. — View Citation
Bourantas CV, Farooq V, Onuma Y, Piazza N, Van Mieghem NM, Serruys PW. Transcatheter aortic valve implantation: new developments and upcoming clinical trials. EuroIntervention. 2012 Sep;8(5):617-27. doi: 10.4244/EIJV8I5A94. — View Citation
Brown JM, O'Brien SM, Wu C, Sikora JA, Griffith BP, Gammie JS. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J — View Citation
Chiam PT, Ruiz CE. Percutaneous transcatheter aortic valve implantation: Evolution of the technology. Am Heart J. 2009 Feb;157(2):229-42. doi: 10.1016/j.ahj.2008.10.003. — View Citation
Dewey TM, Brown DL, Das TS, Ryan WH, Fowler JE, Hoffman SD, Prince SL, Herbert MA, Culica D, Mack MJ. High-risk patients referred for transcatheter aortic valve implantation: management and outcomes. Ann Thorac Surg. 2008 Nov;86(5):1450-6; discussion 1456-7. doi: 10.1016/j.athoracsur.2008.07.043. — View Citation
Hara H, Pedersen WR, Ladich E, Mooney M, Virmani R, Nakamura M, Feldman T, Schwartz RS. Percutaneous balloon aortic valvuloplasty revisited: time for a renaissance? Circulation. 2007 Mar 27;115(12):e334-8. doi: 10.1161/CIRCULATIONAHA.106.657098. No abstract available. — View Citation
Holmes DR Jr, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, Calhoon JH, Carabello BA, Desai MY, Edwards FH, Francis GS, Gardner TJ, Kappetein AP, Linderbaum JA, Mukherjee C, Mukherjee D, Otto CM, Ruiz CE, Sacco RL, Smith D, Thomas JD. 2012 ACCF/A — View Citation
Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart — View Citation
Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlke-Barwolf C, Boersma E, Ravaud P, Vahanian A. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005 Dec;26(24):2714-20. doi: 10.1093/eurheartj/ehi471. Epub 2005 Sep 1. — View Citation
Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010 Oct 21;363(17):1597-607. doi: 10.1056/NEJMoa1008232. Epub 2010 Sep 22. — View Citation
Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993 Apr;21(5):1220-5. doi: 10.1016/0735-1097(93)90249-z. — View Citation
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006 Sep 16;368(9540):1005-11. doi: 10.1016/S0140-6736(06)69208-8. — View Citation
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth L — View Citation
Saia F, Marrozzini C, Dall'Ara G, Russo V, Martin-Suarez S, Savini C, Ortolani P, Palmerini T, Taglieri N, Bordoni B, Pilato E, Di Bartolomeo R, Branzi A, Marzocchi A. How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation? J Cardiovasc Med (Hagerstown). 2010 Oct;11(10):727-32. doi: 10.2459/JCM.0b013e328338940f. — View Citation
Thomas M. The global experience with percutaneous aortic valve replacement. JACC Cardiovasc Interv. 2010 Nov;3(11):1103-9. doi: 10.1016/j.jcin.2010.10.001. — View Citation
Thourani VH, Myung R, Kilgo P, Thompson K, Puskas JD, Lattouf OM, Cooper WA, Vega JD, Chen EP, Guyton RA. Long-term outcomes after isolated aortic valve replacement in octogenarians: a modern perspective. Ann Thorac Surg. 2008 Nov;86(5):1458-64; discussion 1464-5. doi: 10.1016/j.athoracsur.2008.06.036. — View Citation
Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007 Jan;28(2):230-68. doi: 10.1093/eurheartj/ehl428. Epub 2007 Jan 26. No abstract available. — View Citation
Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg. 2006 Dec;82(6):2111-5. doi: 10.1016/j.athoracsur.2006.07.048. — View Citation
* Note: There are 20 references in all — Click here to view all references
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Safety endpoints adjudicated by an independent Clinical Events Committee (CEC) | Mortality: all-cause, cardiovascular, and non-cardiovascular Stroke: disabling and non-disabling Myocardial infarction (MI): periprocedural (=72 hours post index procedure) and spontaneous (>72 hours post index procedure) Bleeding: life-threatening (or disabling) and major Acute kidney injury (=7 days post index procedure): based on the AKIN System Stage 3 (including renal replacement therapy) or Stage 2 Major vascular complication Repeat procedure for valve-related dysfunction (surgical or interventional therapy) Hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV) | peri- and post-procedure, at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 , 12, 24, 36, 48 & 60 months post index procedure | |
| Other | Device Performance | Successful vascular access, delivery and deployment of the study valve, and successful retrieval of the delivery system Successful retrieval of the study valve if retrieval is attempted Successful repositioning of the study valve if repositioning is attempted Grade of aortic valve regurgitation: paravalvular, central, and combined | peri- and post-procedure, at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 , 12, 24, 36, 48 & 60 months post index procedure | |
| Other | Procedural success | device and/or procedure related serious adverse events (SAEs) and death, correct positioning of a single transcatheter valve into the proper anatomical location, intended performance of the study device (effective orifice area [EOA] >0.9 cm2 for BSA <1.6 m2 and EOA >1.1 cm2 for BSA =1.6 m2 plus either a mean aortic valve gradient <20 mm Hg or a peak velocity <3m/sec, and no moderate or severe prosthetic valve aortic regurgitation) at discharge or 7 days post-procedure (whichever comes first) | peri- and post-procedure, at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 , 12, 24, 36, 48 & 60 months post index procedure | |
| Other | prosthetic aortic valve performance as measured by transthoracic echocardiography (TTE) | assessed by an independent core laboratory, including effective orifice area, mean and peak aortic gradients, peak aortic velocity, and grade of aortic regurgitation | peri- and post-procedure, at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 , 12, 24, 36, 48 & 60 months post index procedure | |
| Other | New York Heart Association (NYHA) | New York Heart Association (NYHA) functional classification | peri- and post-procedure, at discharge or 7 days post-procedure (whichever comes first), 30 days, 6 , 12, 24, 36, 48 & 60 months post index procedure | |
| Other | Paravalvular aortic regurgitation | Moderate or greater paravalvular aortic regurgitation (based on core lab assessment) at 30 days and 12 months | At 30 days and 12 months | |
| Primary | All-cause mortality | All-cause mortality through 30 days post index procedure. | Through 30 days post index procedure | |
| Primary | Mean aortic valve pressure gradient | Mean aortic valve pressure gradient at 30 days post index procedure. | At 30 days post index procedure |